Another double-blind placebo-controlled trial of 102 participants with T2DM reported that liraglutide downregulates circulating ceramides, phospholipids, and triglycerides, which further strengthens the recommendation of GLP-1 receptor agonists to prevent cardiovascular disease in T2DM (47). This evidence concerns the gene GLP1R and cardiovascular disorder.